James J. Ignatz-Hoover

Author

Also Known As

J J Ignatz-Hoover, James Ignatz-Hoover, James Ignatz‐Hoover, James J Ignatz-Hoover, James J. Ignatz-Hoover, James John Ignatz-Hoover

189

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Case Western Reserve University University School University Hospitals Cleveland Medical Center University Hospitals of Cleveland University Hospitals Seidman Cancer Center

About

James J. Ignatz-Hoover is an author at Case Western Reserve University specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	319
2	Cell Biology	4	4	171
3	Immunology	4	4	298
4	Natural Sciences	1	1	21
5	Gastroenterology	1	1	148

James J. Ignatz-Hoover

Publications

414

Citations

H-Index

Page 1

	Year	Citations
Circulating <scp>CD</scp>4<sup>+</sup> and <scp>CD</scp>8<sup>+</sup> T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation Nicholas Funderburg, Samantha R. Stubblefield Park, Hannah C. Sung, Immunology Chronic Inflammatory DiseasesImmune RegulationImmunologyPathologyGastroenterology	2013	148
The role of TLR8 signaling in acute myeloid leukemia differentiation James J. Ignatz-Hoover, Huaiyu Wang, Stephen Moreton, Leukemia Hematological MalignancyMixed-phenotype Acute LeukemiaImmunologyHematologyAutoimmunity	2014	70
GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation Kalpana Gupta, Tammy Stefan, James J. Ignatz-Hoover, Cancer Research Hematological MalignancyCell RegulationMixed-phenotype Acute LeukemiaAcute Myeloid LeukemiaReceptor Tyrosine Kinase	2016	44
A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity Sophia Hu, Masumi Ueda, Lindsay Stetson, Molecular Cancer Therapeutics Hematological MalignancyNovel TherapyStandard TherapiesAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2016	36
Aberrant GSK3β nuclear localization promotes AML growth and drug resistance James J. Ignatz-Hoover, Victoria Wang, Nathan Mackowski, Blood Advances	2018	27
Silencing near tRNA genes is nucleosome-mediated and distinct from boundary element function Paul D. Good, Ann Kendall, James J. Ignatz-Hoover, Gene ChromatinTranscriptional RegulationChromatin StructureChromatin RemodelingNatural Sciences	2013	21
Interleukin-12 Is the Optimum Cytokine To Expand Human Th17 Cells In Vitro Soad Nady, James J. Ignatz-Hoover, Mohamed Tarek M. Shata Clinical and Vaccine Immunology	2009	21
Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity Priyanka S. Rana, James J. Ignatz-Hoover, Chunna Guo, Molecular Cancer Therapeutics	2024	19
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial Ehsan Malek, Priyanka S. Rana, Muthulekha Swamydas, Nature Communications	2024	18
Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia Masumi Ueda, Tammy Stefan, Lindsay Stetson, Frontiers in Oncology	2020	10

Page 1